Fig. 4
From: Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter
The expression of CD271 determines melanoma cell properties. a Expression of CD271 in two representative CD271high brain metastases (BM; 13, 8) as well of a melanotic CD271low BM (7), as determined by immunohistochemistry. b Upper panel: Co-staining of CD271 (red) and MITF (brown) of a CD271high BM (1). Lower panel: relative expression of CD271, MITF-M or MET in melanoma cells either positively (CD271+) or negatively (CD271−) sorted for CD271 or unsorted (Bulk). c Levels of expression of MET, CD271 and MITF-M in CD271high and CD271low BM from two independent studies (GSE50493 and GSE44660). P-values were determined using the Wilcoxon rank sum test. d CD271-dependent regulation of DNA-repair genes in T20/02CD271/NGFR (left panel) or cells stably transfected with CD271-specific shRNAs (#2, #3, #4) by qPCR (right panel). Log2 relative expression levels ± SD of independent triplicates, compared to cells either expressing GFP or knock-down controls (shCtl.) are shown. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. e Melanoma cells (A375, MeWo) engineered to stably express CD271 and drug-resistant (Fote, Vind) cells show a higher migratory than control cells (GFP). Contrary, the CD271 knock-down (sh#3) strongly decreased cell migration as determined by Live-cell imaging-based scratch-wound assays. Wound closure is indicated by the wound width in μm